Trial of sunitinib plus paclitaxel for advanced breast cancer discontinued
Pfizer is discontinuing a phase 3 study of sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for the first-line treatment of patients with advanced breast cancer.
Pfizer is discontinuing a phase 3 study of sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for the first-line treatment of patients with advanced breast cancer. An independent data monitoring committee stated that treatment with sunitinib plus paclitaxel would not meet the primary end point of superior progression-free survival versus bevacizumab plus paclitaxel.
Other trials of sunitinib have not been affected, including a phase 3 trial evaluating sunitinib plus docetaxel versus docetaxel alone for the first-line treatment of advanced breast cancer and a phase 3 trial evaluating sunitinib plus capecitabine versus capecitabine alone for the second-line treatment of advanced breast cancer.
Pfizer announced in April that it was discontinuing a phase 3 study of sunitinib as monotherapy for the treatment of advanced breast cancer (see Sunitinib trial for advanced breast cancer discontinued).
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
